A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: An exploratory proof of concept study

International Journal of COPD

Volumn 9, Issue , 2014, Pages 533-542

  Sohal, Sukhwinder Singh ^a   Soltani, Amir ^a   Reid, David ^a,b   Ward, Chris ^a,c   Wills, Karen E ^a,d   Muller, H Konrad ^a   Walters, Eugene Haydn ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF TASMANIA   (Australia)

Author keywords

EGFR; Lung cancer; MMP 9; Pilot trial; Reticular basement membrane; S100A4

Indexed keywords

CALVASCULIN; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUTICASONE PROPIONATE; GELATINASE B; PLACEBO; ANDROSTANE DERIVATIVE; BIOLOGICAL MARKER; EGFR PROTEIN, HUMAN; FLUTICASONE; MMP9 PROTEIN, HUMAN; PROTEIN S 100; S100A4 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL ACTIVATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY EPITHELIUM; AGED; AIRWAY REMODELING; AUSTRALIA; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PILOT STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; AIRWAY REMODELING; ANDROSTADIENES; AUSTRALIA; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LUNG; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, EPIDERMAL GROWTH FACTOR; S100 PROTEINS; TREATMENT OUTCOME;

EID: 84901495942     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S63911     Document Type: Article

References (39)

1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364(9434):613-620.
2. Feltis BN, Wignarajah D, Zheng L, etal. Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Am J Respir Crit Care Med. 2006;173(11):1201-1207.
3. Sohal SS, Reid D, Soltani A, etal. Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology. 2010;15(6):930-938.
4. Sohal SS, Reid D, Soltani A, etal. Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respir Res. 2011;12:130.
5. Sohal SS, Walters EH. Epithelial mesenchymal transition (EMT) in small airways of COPD patients. Thorax. 2013;68(8):783-784.
6. Sohal SS, Walters EH. Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD). Respir Res. 2013;14:120.
7. Sohal SS, Ward C, Danial W, Wood-Baker R, Walters EH. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2013;7(3):275-288.
8. Sohal SS, Soltani A, Weston S, Wood-Baker R, Walters EH. Intermediate filament vimentin and potential role in epithelial mesenchymal transition (EMT). In: De Mello RA, editor. Vimentin Concepts and Molecular Mechanisms. New York: Nova Publishers; 2013: 37-61.
9. Soltani A, Muller HK, Sohal SS, etal. Distinctive characteristics of bronchial reticular basement membrane and vessel remodelling in chronic obstructive pulmonary disease (COPD) and in asthma: they are not the same disease. Histopathology. 2012;60(6):964-970.
10. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429-1437.
11. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-1428.
12. Soltani A, Reid DW, Sohal SS, etal. Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study. Respir Res. 2010;11:105.
13. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112(12):1776-1784.
14. Young R, Hopkins R, Etzel C, El-Zein R. Genetics of lung cancer susceptibility and COPD. Lancet Oncol. 2011;12(7):622-623.
15. Garber K. Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. J Natl Cancer Inst. 2008;100(4):232-233, 239.
16. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6): 912-919.
17. Reid DW, Wen Y, Johns DP, Williams TJ, Ward C, Walters EH. Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. Respirology. 2008;13(6):799-809.
18. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(7):712-719.
19. Kiri VA, Fabbri LM, Davis KJ, Soriano JB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med. 2009;103(1):85-90.
20. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol. 2010;10:67.
21. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10(2):307-312.
22. Sohal SS, Reid D, Soltani A, etal. Changes in airway histone deacetylase2 in smokers and COPD with inhaled corticosteroids: a randomized controlled trial. PLoS One. 2013;8(5):e64833.
23. Richmond I, Booth H, Ward C, Walters EH. Intrasubject variability in airway inflammation in biopsies in mild to moderate stable asthma. Am J Respir Crit Care Med. 1996;153(3):899-903.
24. Luepker RV, Raczynski JM, Osganian S, etal. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA. 2000;284(1):60-67.
25. Ward C, Forrest IA, Murphy DM, etal. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax. 2005;60(10):865-871.
26. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009;119(6):1417-1419.
27. Milara J, Peiro T, Serrano A, Cortijo J. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. Thorax. 2013;68(5):410-420.
28. Wang Q, Wang Y, Zhang Y, Zhang Y, Xiao W. The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res. 2013;14:67.
29. Dasari V, Gallup M, Lemjabbar H, Maltseva I, McNamara N. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"? Am J Respir Cell Mol Biol. 2006;35(1):3-9.
30. Barnes PJ, Adcock IM. Chronic obstructive pulmonary disease and lung cancer: a lethal association. Am J Respir Crit Care Med. 2011;184(8): 866-867.
31. Yang IA, Relan V, Wright CM, etal. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin Ther Targets. 2011;15(4):439-456.
32. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med. 2002;165(12):1592-1596.
33. Chanez P, Bourdin A, Vachier I, Godard P, Bousquet J, Vignola AM. Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(3): 184-190.
34. Greenberg AK, Hu J, Basu S, etal. Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators. Am J Respir Cell Mol Biol. 2002;27(3):320-328.
35. Yao R, Wang Y, Lemon WJ, Lubet RA, You M. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene. 2004;23(46):7746-7752.
36. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 1997;57(24):5489-5492.
37. Calverley PM, Anderson JA, Celli B, etal. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
38. Miller YE, Keith RL. Inhaled corticosteroids and lung cancer chemoprevention. Am J Respir Crit Care Med. 2007;175(7):636-637.
39. van Gestel YR, Hoeks SE, Sin DD, etal. COPD and cancer mortality: the influence of statins. Thorax. 2009;64(11):963-967.